News

Prestige Consumer Healthcare (PBH) reported $276.99 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 3.1%. EPS of $1.02 for the same period compares to $1.07 a year ago.

The reported revenue represents a surprise of -3.46% over the Zacks Consensus Estimate of $286.91 million. With the consensus EPS estimate being $1.14, the EPS surprise was -10.53%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Prestige Consumer Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- OTC Healthcare- International: $45.86 million versus the two-analyst average estimate of $44.58 million. The reported number represents a year-over-year change of +5.3%.
• Revenues- OTC Healthcare- North American: $231.13 million versus the two-analyst average estimate of $242.49 million. The reported number represents a year-over-year change of -4.6%.
• Gross profit- OTC Healthcare- North American: $125.40 million versus $137.07 million estimated by two analysts on average.
• Gross profit- OTC Healthcare- International: $26.42 million versus $25.83 million estimated by two analysts on average.

View all Key Company Metrics for Prestige Consumer Healthcare here>>>

Shares of Prestige Consumer Healthcare have returned +3.5% over the past month versus the Zacks S&P 500 composite's +2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.